MediRama partners with U.S. anticancer 에볼루션 바카라 사이트 specialist CRO ‘TD2 Oncology’
Laying the groundwork for Korean biotechnology firms’ expansion into the U.S.
[by Yu, Suin] MediRama, a clinical contract research organization (CRO) specializing in oncology, announced on June 26 that it has entered into a global clinical collaboration partnership with TD2 Oncology (The Translational 에볼루션 바카라 사이트 Development Institute), a U.S.-based CRO specializing in anticancer 에볼루션 바카라 사이트 development. This strategic alliance is anticipated to serve as a foundation for providing a comprehensive clinical pathway for Korean biotech firms and startups aiming to penetrate the U.S. market, encompassing the full spectrum from early-phase clinical trials to U.S. Food and 에볼루션 바카라 사이트 Administration (FDA) registration.
Leveraging its clinical operational expertise in Korea and the Asian region, MediRama has supported domestic biotechnology companies in formulating clinical development strategies, initiating early-phase (Phase 1) clinical trials for anticancer 에볼루션 바카라 사이트s, and facilitating connections with the U.S. market.
Through this agreement, both parties intend to offer tailored joint services to Korean firms pursuing
anticancer 에볼루션 바카라 사이트 development in the United States. These services will include access to a network of U.S. hospitals, collaboration with expert researchers, and strategic support for regulatory submissions and compliance.
“A successful clinical trial in the United States serves as a critical turning point for attracting investment and facilitating technology export,” said Moon Hanlim, CEO of MediRama. “We aim to deliver practical solutions that enable Korean biotech startups to enter the U.S. clinical market swiftly and efficiently,” she added.
“This agreement represents the launch of a powerful strategic partnership between two leading CROs with complementary strengths in oncology 에볼루션 바카라 사이트 development and clinical trial execution,” expressed Dr. Stephen Gately, President and CEO of TD2 Oncology. “Together, we will advance our shared mission of transforming cancer treatment and improving patient outcomes.”